H.R. 1227: Alternatives to PAIN Act

H.R. 1227 would change Medicare Part D rules so some non-opioid pain medicines get better insurance treatment than they do now. If a drug qualifies, Medicare drug plans could not apply the Part D deductible to it, and the drug would have to be placed on the plan's lowest cost-sharing tier. That means patients would likely pay less out of pocket for these drugs than they do today.

The bill also targets two common insurance barriers: step therapy and prior authorization. Under this proposal, Medicare drug plans could not require a patient to use an opioid first before getting a qualifying non-opioid pain drug, and they could not require prior approval before covering that drug. Supporters will argue this is a direct response to concerns that insurance rules can push patients toward cheaper opioid options even when a non-opioid drug may be appropriate.

But the bill is narrower than it may sound. It applies only to non-opioid pain drugs that meet several tests: they must be FDA-approved for postoperative or other acute pain, must not work on opioid receptors, must lack a therapeutically equivalent marketed alternative, and must stay under a set monthly price ceiling tied to Medicare's specialty-tier threshold. In practice, that means the bill appears aimed at a relatively small set of newer brand-name pain treatments, not the full universe of non-opioid pain care.

Politically, the measure fits into a larger bipartisan push to address addiction risk without cutting off pain treatment. The appeal is easy to understand: reduce incentives that may steer patients to opioids. The harder question is whether lowering cost-sharing and blocking utilization controls for a select class of drugs will raise Medicare spending or favor a small number of manufacturers. That tradeoff is likely to be central as the bill moves through committee.